ALKS FY 2021 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.2B+13.0% YoY

Gross Profit

$976M83.2% margin

Operating Income

$98M8.3% margin

Net Income

-$48M-4.1% margin

EPS (Diluted)

$-0.30

Cash Flow

Operating Cash Flow

$102M

Free Cash Flow

$73M

Stock-Based Comp.

$88M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$912M

Stockholders' Equity

$1.1B

Cash & Equivalents

$338M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.0B	+13.0%
Gross Profit	$976M	$860M	+13.5%
Operating Income	$98M	-$112M	+186.9%
Net Income	-$48M	-$111M	+56.6%